Cost of Revenue Comparison: Geron Corporation vs Travere Therapeutics, Inc.

Biotech Cost Dynamics: Geron vs. Travere

__timestampGeron CorporationTravere Therapeutics, Inc.
Wednesday, January 1, 20148901000570979
Thursday, January 1, 201595740002185000
Friday, January 1, 2016146950004554000
Sunday, January 1, 201784370003605000
Monday, January 1, 2018127230005527000
Tuesday, January 1, 2019512720005234000
Wednesday, January 1, 2020500520006126000
Friday, January 1, 20217830006784000
Saturday, January 1, 20228680007592000
Sunday, January 1, 202312374000011450000
Loading chart...

Unveiling the hidden dimensions of data

Cost of Revenue: A Tale of Two Biotech Companies

In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This chart provides a fascinating comparison of the cost of revenue between Geron Corporation and Travere Therapeutics, Inc. over the past decade.

From 2014 to 2023, Geron Corporation's cost of revenue has shown significant fluctuations, peaking in 2023 with a staggering 1,237% increase compared to 2014. This dramatic rise highlights the company's aggressive investment in research and development. In contrast, Travere Therapeutics, Inc. has maintained a more stable cost structure, with a modest 100% increase over the same period, reflecting a steady growth strategy.

The data reveals a compelling narrative of two companies navigating the biotech landscape with distinct approaches. As the industry continues to evolve, these insights offer valuable lessons on the impact of cost management on long-term success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025